ECCO 2024

The quest for predictive markers goes on...

S1P-Modulators from a safety perspective

Real-world data from a H2H-study on Vedolizumab vs.…

Primary sclerosing cholangitis – lessons from a large…

A spotlight on the PROFILE study

Combination of different drug classes - risks and…

Treatment targets in 2024 - a silent revolution

Cell-based therapies: The end of the story or the…

IL-23 in UC

Ustekinumab first, anti-p19 second?

Next chapter in S1P- and JAK-inhibition

Obefazimod & IL23R-CAR-Tregs - new molecules in focus

Results of the phase II PIZZICATO (ritlecitinib &…

VIVID 1: Mirikizumab in Crohn's Disease

Tregs - a treatment for the future?

Mirikizumab in crohn's disease

Changing the PROFILE of how we treat CD

Mirikizumab vs Ustekinumab

Mirikizumab in moderate to severe Crohn’s disease:…

Darvadstrocel for complex perianal fistulas and Crohn’s…

VIVID 1: Comparison of mirikizumab with ustekinumab in…

Mirikizumab bei Morbus Crohn

VIVID 1- Comparação do Mirikizumab com o Ustecinumab na…

Mirikizumab vs Ustekinumab

Mirikizumab στη θεραπεία της μέτριας προς βαρειά NC:…

Resultaten van de fase 2 PIZZICATO (ritlecitinib &…

Mirikizumab in anti-TNF failures with UC

Long term outcome of Obefazimod in UC

VTX002 (S1P-modulator) & obefazimod in ulcerative…

The efficacy of biologics and small molecules in…

Risankizumab & guselkumab in ulcerative colitis

VTX-002 in pazienti con colite ulcerosa da moderata a…

VTX002 (S1P-Modulator) & Obefazimod bei Colitis…

Risankizumab & Guselkumab bei Colitis Ulcerosa

lange-termijns uitkomst van obefazimod in UC

Therapy in transition

Still a long road ahead in standards of care in IBD –…

Therapie im Umbruch

Marzenia a rzeczywistość – wyniki ankiety E-QUALITY na…

Biomarker for biological loss of response in CD?

Should we proactively treat CD-patients having small…

PROFILE: Biomarkers not successfull for therapy…

Results from the PROFILE-trial

Early intervention in Crohn´s disease therapy

Changing treatment paradigm in CD

PROFILE: practice-changing results

Cambiano i paradigmi di trattamento nelle malattie di…

Risultati dallo studio PROFILE

Biomarker for biological loss of response in CD?

Intervenção terapêutica precoce na doença de Crohn

Faut-il traiter les patients avec les lesions de Crohn…

Injection de cellules souches mesenchimateuses…

Guselkumab & Golimumab have complementary effects when…

Vers un traitement plus agressif de la colite aigüe…

Use of CAR-Tregs in IBD: preclinical data

Therapy in transition

Personalized treatment in IBD: reality or hype?

Immunohomeostasis by regulatory CAR-T cells!?

Therapie im Umbruch

Utilizzo di cellule CAR Tregs nelle MICI: dati…

gepersonaliseerde aanpak van IBD: realiteit of hype?

Immunohomöstase durch regulatorische CAR-T-Zellen!?

End of the Kono-S legend!

MIRACLE project: Avoidance of protective Ileostomy

Extended mesenterectomy is not superior to mesenteric…

Implication of proctocolectomy in patients affected by…

Colectomy and the natural history of PSC – lessons form…

Randomised clinical trials finally coming to IBD…

Η εκτεταμένη εκτομή του μεσεντερίου δεν υπερέχει της…

Implicazioni della proctocolectomia in pazienti affetti…

La fin de la legende du Kono-S!

Kolektomia a historia naturalna PSC – czy istnieje…

MIRACLE-Projekt: Verzicht auf protektive Ileostomie

Transcriptomic profiles in patients with UC receiving…

Análise do Transcriptoma em doentes com colite ulcerosa…